M/s. Planet Pharma Pharmaceutical Import Profile — France (DGFT 2022–2026)

Name: M/s. Planet Pharma Pharmaceutical Import Records from India — 4 Products, $2.8M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

M/s. Planet Pharma — Pharmaceutical Importer Profile (2026) | 4 Products, $2.8M Trade | TransData Nexus

M/s. Planet Pharma

Pharmaceutical Importer · France · Medical Devices & Diagnostics Focus · $2.8M Total Trade · DGFT Verified

M/s. Planet Pharma is a pharmaceutical importer based in France with a total trade value of $2.8M across 4 products in 3 therapeutic categories. Based on 159 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. M/s. Planet Pharma sources from 7 verified Indian suppliers, with Sun Pharmaceutical Industries Limited accounting for 42.1% of imports.

M/s. Planet Pharma — Import Portfolio & Supplier Network

M/s. Planet Pharma import network — 4 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to M/s. Planet Pharma?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Sun Pharmaceutical Industries Limited	$818.7K	48	42.1%
Aurochem Pharmaceuticals India Privatelimited	$673.7K	52	34.7%
Aurochem Pharmaceuticals India Private Limited

What Formulations Does M/s. Planet Pharma Import?

Formulation	Value	Ships
Bonecare	$213.9K	5
Solfer syrup	$139.7K	6
Zolcer kit	$100.0K	2
Bacqure INJ 500 MG 30ML 1 s fwa Pack 1vial batch	$100.0K	2
Ranferon plus cap 3x10s fwa Pack 03 10batch	$68.1K	3
Feverlet	$59.3K	3
Scarid gel	$51.2K	4
Pharmaceutical products solfer	$50.0K	1
Pharmaceutical products auromox duo 1000 amoxicillin and clavulanate potassiumtablets USP Each film coated tablet	$50.0K	1
Synriam TAB 150 750MG Pack 03 tablets batch dfg2314a dfg2315a Each film coatedtab conts arterolane maleate eq to	$50.0K	1
Brustan TAB Pack box20s batch dfg2393b Each film coated TAB conts ibuprofen BP 400MG paracetamol BP 325MG	$39.5K	2
Ranferon 12 CAPS Pack 30 capsule batch xka0022 xka0017 xka0020 xka0021 Each cpas conts vitamin a apamitate 1 7miu	$38.7K	1
Volini gel 30GM linseed oil BP 3 0 w wdiclofenac diethyl amine BP 1 16 w w Pack 30GM tubek batch sxg0846a eq to	$35.5K	2
Bacqure INJ 500 MG 30ML 1 s fwa Pack 1 vial batch	$34.5K	2
Brustan tablets knya 10s Pack : 10s strip batch : dfe6615a	$33.7K	1

M/s. Planet Pharma imports 99 distinct pharmaceutical formulations. Showing top 15 by value. For full formulation-level data, contact TransData Nexus.

Import Portfolio — Top 4 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Strip	Medical Devices & Diagnostics	$2.0M	111	1.0%	20
2	Volini	Brand Names & OTC Products	$402.3K	22	12.5%	3
3	Chondroitin	Nutritional Supplements	$279.2K	18	2.4%	7
4	Glucosamine	Nutritional Supplements	$183.9K	8	1.4%	13

M/s. Planet Pharma imports 4 pharmaceutical products across 3 categories into France totaling $2.8M.

M/s. Planet Pharma — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

M/s. Planet Pharma is a pharmaceutical importer based in Le Grand-Quevilly, France. The company specializes in sourcing finished pharmaceutical formulations, including tablets, capsules, syrups, and injections, primarily from India. With a total import value of $2.8 million USD over 159 shipments from 2022 to 2026, Planet Pharma plays a significant role in the French pharmaceutical distribution network. The company's product portfolio encompasses four distinct products across three therapeutic categories, indicating a diversified approach to meeting market demands.

In the French pharmaceutical supply chain, Planet Pharma functions as a key importer, facilitating the entry of various pharmaceutical products into the market. By establishing partnerships with multiple Indian suppliers, the company ensures a steady supply of diverse pharmaceutical formulations, contributing to the availability of essential medications within France.

2Distribution Network

Planet Pharma's distribution network is strategically located in Le Grand-Quevilly, France, serving as a central hub for the import and distribution of pharmaceutical products. While specific details regarding warehouse locations and logistics capabilities are not publicly disclosed, the company's consistent import activity suggests a well-organized supply chain capable of efficiently managing the flow of goods from international suppliers to the French market. The geographic coverage primarily focuses on France, with potential for expansion into neighboring European markets, leveraging France's position as a gateway to the European Union.

3Industry Role

In the French pharmaceutical supply chain, Planet Pharma operates as a pharmaceutical importer, sourcing finished pharmaceutical formulations from international suppliers, particularly from India. The company's role is pivotal in ensuring the availability of a diverse range of pharmaceutical products within the French market, thereby supporting the healthcare sector's needs. By importing a variety of products across different therapeutic categories, Planet Pharma contributes to the comprehensive supply of medications, catering to various patient requirements.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — M/s. Planet Pharma

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Planet Pharma's sourcing strategy exhibits a notable concentration, with the top five products accounting for 100% of the total import value. This indicates a high dependency on a limited product range, which could pose risks such as supply chain disruptions or market fluctuations affecting these specific products. The company's reliance on a select group of products suggests a strategic focus on high-demand items, but it also highlights the need for diversification to mitigate potential risks. The shipment data reveals a stable relationship with Indian suppliers, as evidenced by the consistent import activity over the years. However, the lack of diversification in product sourcing may limit Planet Pharma's ability to adapt to changing market demands or regulatory changes affecting specific product categories.

2Supply Chain Resilience

Planet Pharma's supply chain resilience is closely tied to its sourcing strategy. The company's concentration on a limited number of products from a select group of Indian suppliers may expose it to risks associated with supply chain disruptions, such as production delays or regulatory changes in the supplier's country. The absence of publicly available information regarding backup suppliers or alternative sourcing strategies suggests a potential vulnerability in the supply chain. Additionally, the lack of diversification in product formulations imported may limit the company's ability to adapt to shifts in market demand or therapeutic trends. To enhance supply chain resilience, Planet Pharma could consider diversifying its supplier base and product portfolio, thereby reducing dependency on specific suppliers and products.

Importing Pharmaceuticals into France — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for France

1Regulatory Authority & Framework

In France, the primary regulatory authority overseeing pharmaceutical imports is the French National Agency for Medicines and Health Products Safety (ANSM). ANSM is responsible for ensuring the safety, efficacy, and quality of health products, including pharmaceuticals, medical devices, and cosmetics. Key legislation governing pharmaceutical imports includes the Public Health Code, which outlines the requirements for marketing authorization, importation, and distribution of pharmaceutical products. The marketing authorization pathway for Indian generics involves obtaining a Marketing Authorization (MA) from ANSM, which requires submission of comprehensive documentation demonstrating the product's quality, safety, and efficacy. Additionally, compliance with Good Manufacturing Practice (GMP) standards, as recognized by ANSM, is mandatory for all pharmaceutical products imported into France.

2Import Licensing & GMP

Import licensing requirements in France stipulate that all pharmaceutical products must have a valid Marketing Authorization (MA) issued by ANSM. This authorization is contingent upon the product meeting ANSM's standards for quality, safety, and efficacy. Good Manufacturing Practice (GMP) certification is a critical component of the import process. ANSM recognizes GMP certifications from the European Union (EU), the World Health Organization (WHO), and the Pharmaceutical Inspection Co-operation Scheme (PIC/S). Indian exporters seeking to supply pharmaceutical products to France must ensure that their manufacturing facilities are GMP-compliant and that their products have obtained the necessary MA from ANSM. Additionally, wholesale distribution authorization is required for entities involved in the distribution of pharmaceutical products within France, ensuring that all intermediaries in the supply chain adhere to regulatory standards.

M/s. Planet Pharma — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Planet Pharma's product strategy focuses on importing pharmaceutical formulations that cater to specific therapeutic areas, including medical devices and diagnostics, nutritional supplements, and brand-name over-the-counter (OTC) products. The company's top five imported products—strip, Volini, chondroitin, and glucosamine—align with these therapeutic categories, indicating a strategic focus on high-demand products within these segments. The market demand for these products is driven by factors such as an aging population, increasing health awareness, and a growing preference for self-medication, which collectively contribute to the sustained demand for these pharmaceutical formulations in France.

2Sourcing Profile

Planet Pharma's sourcing strategy is centered on importing generic pharmaceutical formulations from India, focusing on products that are in high demand within the French market. The company's preference for finished pharmaceutical formulations, including tablets, capsules, syrups, and injections, reflects a strategic approach to meeting the diverse needs of the French healthcare sector. India's established reputation for producing high-quality generic pharmaceuticals at competitive prices positions it as a key supplier for Planet Pharma's procurement needs.

3Market Positioning

Seller's Guide — How to Become a Supplier to M/s. Planet Pharma

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to enter Planet Pharma's supply chain by offering a broader range of pharmaceutical formulations that align with the company's strategic focus on high-demand products. By diversifying their product portfolios and ensuring compliance with French regulatory standards, Indian exporters can position themselves as viable alternatives to existing suppliers, potentially securing a position within Planet Pharma's sourcing network.

2Requirements & Qualifications

Indian exporters seeking to supply pharmaceutical products to Planet Pharma and the French market must ensure that their manufacturing facilities are compliant with Good Manufacturing Practice (GMP) standards recognized by the European Union (EU), the World Health Organization (WHO), or the Pharmaceutical Inspection Co-operation Scheme (PIC/S). Additionally, obtaining a valid Marketing Authorization (MA) from the French National Agency for Medicines and Health Products Safety (ANSM) is mandatory. Products must also meet labeling requirements, including information in French and adherence to serialization mandates. Ensuring compliance with these standards is essential for successful market entry and sustained business relationships.

How to Approach

Frequently Asked Questions — M/s. Planet Pharma

What products does M/s. Planet Pharma import from India?

M/s. Planet Pharma imports 4 pharmaceutical products across 3 categories. Top imports: Strip ($2.0M), Volini ($402.3K), Chondroitin ($279.2K), Glucosamine ($183.9K).

Who supplies pharmaceuticals to M/s. Planet Pharma from India?

M/s. Planet Pharma sources from 7 verified Indian suppliers. The primary supplier is Sun Pharmaceutical Industries Limited (42.1% of imports, $818.7K).

What is M/s. Planet Pharma's total pharmaceutical import value?

M/s. Planet Pharma's total pharmaceutical import value from India is $2.8M, based on 159 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does M/s. Planet Pharma focus on?

M/s. Planet Pharma imports across 3 categories. The largest: Medical Devices & Diagnostics (69.5%), Nutritional Supplements (16.3%), Brand Names & OTC Products (14.2%).

Get Full M/s. Planet Pharma Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Profile aggregates 4 company name variants from customs records. For current shipment-level data, contact TransData Nexus.